Best Countries for Biotech Company

Choosing the right jurisdiction for a biotech company is one of the most consequential decisions a founder or investor will make. The country where you incorporate and operate determines your regulatory timeline to market, your access to public and private capital, your effective tax rate on intellectual property income, and the depth of the scientific talent pool available to you. This guide analyses the leading jurisdictions - the United States, United Kingdom, Switzerland, Singapore, Ireland, and the Netherlands - across the dimensions that matter most to biotech entrepreneurs: regulatory environment, IP protection, tax incentives, funding ecosystems, and practical formation costs.

A biotech company is a science-driven enterprise whose commercial value depends heavily on intellectual property, regulatory approvals, and long development timelines. Unlike a software startup, a biotech venture may spend a decade and tens of millions of dollars before generating revenue. Jurisdiction selection therefore involves a different calculus than for most businesses.

The key dimensions to evaluate are:

• Regulatory pathway: how long does approval take, and how predictable is the process?
• IP regime: does the country offer patent-box or knowledge-box tax treatment on royalty income?
• R&D incentives: are there cash refunds or tax credits for qualifying research expenditure?
• Talent and infrastructure: are there universities, research hospitals, and contract research organisations nearby?
• Capital access: is there a mature venture capital market, and are public listings accessible?

No single country leads on every dimension. The right choice depends on your stage, your therapeutic area, your investor base, and your long-term commercialisation strategy.

The United States remains the dominant global hub for a biotech company. The Food and Drug Administration (FDA) operates one of the most sophisticated drug and biologics review systems in the world, and FDA approval is widely regarded as the gold standard that unlocks global market access. The Breakthrough Therapy Designation and Fast Track programmes can compress review timelines significantly for products addressing unmet medical needs.

The US offers deep venture capital markets, particularly in the Boston-Cambridge corridor, the San Francisco Bay Area, and the Research Triangle in North Carolina. Nasdaq';s dedicated biotech index and the ability to access the public markets through an initial public offering or a special purpose acquisition company give US-listed biotech companies a liquidity path unavailable in most other jurisdictions.

From a tax perspective, the US federal corporate rate sits at a level that is not the lowest globally, but the research and development tax credit under Section 41 of the Internal Revenue Code provides meaningful relief. Many states layer additional incentives on top. Delaware remains the preferred state of incorporation for venture-backed companies because of its predictable corporate law, the Court of Chancery, and the familiarity of institutional investors with Delaware entities.

A common mistake among foreign founders is underestimating the cost and complexity of FDA engagement. Pre-IND meetings, Investigational New Drug applications, and Phase I through Phase III trial management require specialist regulatory counsel from the outset. Professional fees for regulatory strategy alone can run into the high tens of thousands of dollars annually before a single clinical trial begins.

In practice, founders should consider establishing a US holding company even if core research operations remain elsewhere. Many US venture funds are structurally unable to invest in non-US entities, making a Delaware C-corporation the default for any company seeking institutional US capital.

The United Kingdom has positioned itself as a leading European destination for a biotech company, particularly following its departure from the European Union';s regulatory framework. The Medicines and Healthcare products Regulatory Agency (MHRA) now operates independently of the European Medicines Agency (EMA), which creates both an opportunity and a complexity. Companies can seek UK approval on a timeline that is no longer tied to EMA processes, and the MHRA has introduced the Innovative Licensing and Access Pathway (ILAP) to accelerate promising therapies.

The UK';s most compelling advantage for biotech is its R&D tax credit regime. The Research and Development Expenditure Credit (RDEC) scheme allows large companies to claim a taxable credit on qualifying R&D expenditure, while the SME scheme historically offered even more generous relief, including cash refunds for loss-making companies. Recent reforms have merged elements of these schemes, but the UK remains one of the most generous jurisdictions globally for R&D incentives measured as a percentage of qualifying spend.

The UK also benefits from a strong university ecosystem - Oxford, Cambridge, Imperial College London, and University College London all have active technology transfer offices and spin-out programmes. The Golden Triangle of London, Oxford, and Cambridge has produced a disproportionate share of European biotech successes.

Corporate tax in the UK has risen in recent years, but the Patent Box regime allows companies to apply a reduced effective rate to profits attributable to patented inventions. This makes the UK attractive for companies that expect to generate royalty income or product sales from patented assets.

A non-obvious requirement for foreign founders is the need to establish genuine substance in the UK to access both the R&D credits and the Patent Box. HMRC scrutinises claims carefully, and companies that maintain only a brass-plate presence risk having claims disallowed. Qualified scientific staff, laboratory space, and documented R&D activity are expected.

Switzerland is a preferred jurisdiction for a biotech company that prioritises IP holding, regulatory proximity to Europe, and access to a highly skilled scientific workforce. Switzerland is not an EU member but maintains bilateral agreements that give Swiss companies significant access to European markets, and the Swiss regulatory authority Swissmedic operates with a reputation for rigour and predictability.

The Swiss cantonal tax system creates meaningful variation in effective corporate tax rates depending on where a company locates. Cantons such as Zug, Nidwalden, and Lucerne have historically offered competitive rates, and the federal participation exemption and IP box regime - introduced under the OECD-compliant reform of the Swiss tax system - allow companies to shelter a portion of qualifying IP income from cantonal and federal tax.

Switzerland';s life sciences cluster is centred on the Basel-Zurich corridor, home to major pharmaceutical multinationals, contract manufacturers, and a dense network of specialist service providers. This concentration of industry creates a talent market that, while expensive, is deep and experienced.

Formation costs in Switzerland are higher than in most jurisdictions. A GmbH (limited liability company) requires minimum share capital, and a notarised deed of incorporation is mandatory. Professional fees for formation, combined with ongoing audit and accounting requirements, mean that annual compliance costs for a Swiss entity typically start from the mid-thousands of Swiss francs and rise quickly for operating companies.

A common mistake is treating Switzerland purely as a holding location while conducting all R&D elsewhere. Swiss tax authorities apply substance requirements rigorously, and the IP box benefit requires that qualifying IP was developed or significantly improved in Switzerland. Companies that hold IP in Switzerland without corresponding R&D activity face challenges in sustaining their tax position.

Singapore is the leading jurisdiction in Asia-Pacific for a biotech company seeking regional headquarters or a platform for clinical development across Southeast Asia and beyond. The Health Sciences Authority (HSA) is the competent regulatory body for pharmaceuticals and medical devices, and Singapore has bilateral recognition arrangements with several major regulators that can accelerate multi-market approval strategies.

The Economic Development Board (EDB) and the Agency for Science, Technology and Research (A*STAR) actively recruit biotech companies with grant funding, co-investment, and access to public research infrastructure. The Biomedical Sciences cluster in Biopolis, a purpose-built research campus in one-north, provides laboratory space, shared equipment, and proximity to clinical partners at the National University Hospital and Singapore General Hospital.

Singapore';s corporate tax rate is competitive, and the Intellectual Property Development Incentive (IDI) allows qualifying companies to apply a reduced rate to IP income. The Research Incentive Scheme for Companies (RISC) and other EDB programmes can substantially offset early-stage R&D costs through grants rather than tax credits, which is particularly valuable for pre-revenue companies that cannot yet monetise tax losses.

English is an official language, the legal system is based on English common law, and the country';s political stability and rule of law are consistently ranked among the highest globally. These factors make Singapore straightforward for international founders to navigate without specialist local knowledge of a foreign legal tradition.

The practical limitation of Singapore for many biotech companies is market size. Singapore itself is a small domestic market, and clinical trial recruitment requires partnerships across the region. Companies focused on the US or European markets may find that a Singapore entity adds complexity without proportionate benefit unless they have a genuine Asia-Pacific commercial strategy.

If you are evaluating Singapore or another Asia-Pacific jurisdiction for your biotech company structure, contact info@vlolawfirm.com. We can help structure the setup correctly the first time.

Ireland and the Netherlands both offer compelling propositions for a biotech company seeking a European base, though they differ in their strengths.

Ireland';s 12.5% corporate tax rate on trading income is among the lowest in the OECD, and the Knowledge Development Box (KDB) - Ireland';s patent box regime - applies a 6.25% effective rate to qualifying IP income. The KDB is compliant with OECD modified nexus requirements, meaning the IP must have been developed in Ireland to qualify. Ireland is an English-speaking common law jurisdiction, a full EU member, and the preferred European base for many US multinationals, which creates a deep ecosystem of professional services, regulatory expertise, and talent familiar with life sciences compliance.

The Health Products Regulatory Authority (HPRA) is Ireland';s national medicines regulator and also serves as a reference member state within the EMA';s centralised procedure. This gives Irish-incorporated companies a direct line into the EU regulatory process, which is valuable for companies seeking European Medicines Agency approval.

The Netherlands offers a different profile. The Innovation Box regime reduces the effective corporate tax rate on qualifying IP profits to a low single-digit percentage, and the Dutch tax authority (Belastingdienst) is known for its willingness to issue advance tax rulings, giving companies certainty about their tax position before committing to a structure. The Netherlands is home to a strong life sciences cluster centred on Leiden, Utrecht, and Amsterdam, with Leiden Bio Science Park being one of Europe';s largest dedicated life sciences campuses.

A practical scenario: a US-founded biotech company with European clinical ambitions might incorporate a Dutch or Irish entity to hold European IP, conduct European trials, and engage with the EMA, while maintaining a Delaware parent for US investor relations and Nasdaq listing purposes. This dual-entity structure is common and, when properly documented, is accepted by tax authorities on both sides of the Atlantic.

Many underestimate the substance requirements that both Ireland and the Netherlands impose to access their preferential IP regimes. A non-obvious requirement is that qualifying R&D expenditure must be tracked and documented from the earliest stages, because the nexus fraction - which determines what proportion of IP income qualifies for the reduced rate - is calculated based on the ratio of qualifying R&D spend to total R&D spend over the life of the asset.

Formation costs and ongoing compliance burdens vary significantly across the jurisdictions covered in this guide.

In the United States, forming a Delaware C-corporation is relatively inexpensive - state filing fees are modest and the process can be completed in days. However, ongoing compliance costs, including registered agent fees, state franchise taxes, and the cost of maintaining a US-qualified board and officers, add up. For a biotech company with active operations, annual legal and compliance costs in the US typically start from the low tens of thousands of dollars.

In the United Kingdom, company formation through Companies House is straightforward and inexpensive. The more significant costs arise from HMRC compliance, particularly if the company is claiming R&D tax credits, which require detailed technical and financial documentation. Accounting and legal fees for a UK biotech entity with active R&D typically start from the low tens of thousands of pounds annually.

Switzerland is the most expensive jurisdiction for formation and ongoing compliance among those reviewed. Notarial fees, mandatory audit requirements for larger entities, and the cost of qualified local directors mean that a Swiss entity';s annual compliance cost can reach the mid-to-high tens of thousands of Swiss francs even before operational expenses.

Singapore offers a middle path. Formation is fast - a private limited company can be incorporated in one to two business days - and annual compliance costs are moderate. The availability of EDB grants can offset a significant portion of early-stage costs, making Singapore cost-competitive for companies that qualify for incentive programmes.

Ireland and the Netherlands both offer moderate formation costs within the EU framework. The more significant investment is in establishing genuine substance - qualified staff, office space, and documented R&D activity - to access the preferential tax regimes. Companies that treat these jurisdictions as pure holding locations without substance risk losing the tax benefits they sought.

A practical scenario: an early-stage biotech company with limited capital might begin in the UK to access RDEC cash refunds, then establish an Irish or Dutch subsidiary as it approaches commercialisation and needs to optimise IP income taxation. This staged approach is common and can be structured efficiently with advance planning.

What is the single most important factor when choosing a country for a biotech company?

The most important factor depends on your stage of development. For pre-clinical and early clinical companies, access to R&D tax incentives and grant funding often outweighs other considerations, because these mechanisms provide non-dilutive capital when revenue is absent. For companies approaching commercialisation, the regulatory pathway and IP tax treatment become more significant. For companies seeking institutional investment, the jurisdiction';s familiarity to target investors - particularly US venture funds - can be decisive. In practice, most successful biotech companies end up with a multi-jurisdictional structure that optimises across several of these dimensions simultaneously.

How long does it take to establish a biotech company in these jurisdictions, and what are the typical costs?

Formation timelines range from one to two business days in Singapore and the UK to several weeks in Switzerland, where notarial requirements add time. The US (Delaware) typically takes three to five business days for standard formation. Ireland and the Netherlands fall in the one to two week range. However, formation is only the beginning. Establishing the substance required to access preferential tax regimes - hiring qualified staff, securing laboratory space, and beginning documented R&D activity - takes months and involves costs that dwarf the formation fees themselves. Professional fees for legal, tax, and regulatory counsel across the first year of operation typically start from the low tens of thousands in the relevant currency for each jurisdiction.

Can a biotech company be incorporated in one country while conducting clinical trials in another?

Yes, and this is standard practice. Clinical trials are governed by the regulations of the country where the trial sites are located, not the country of incorporation. A company incorporated in Ireland can run trials in Germany, Poland, and the UK simultaneously, provided it complies with the applicable clinical trial regulations in each country - in the EU, the Clinical Trials Regulation (EU) No 536/2014 provides a harmonised framework. The key consideration is ensuring that the corporate structure, IP ownership, and intercompany agreements are aligned so that the economic benefit of the trials accrues to the entity intended to hold the IP and generate the eventual commercial return.

No single country is the best jurisdiction for every biotech company. The US leads on capital access and regulatory prestige; the UK on R&D incentives and talent; Switzerland on IP holding and precision regulation; Singapore on Asia-Pacific positioning and grant funding; Ireland and the Netherlands on EU access and IP tax efficiency. The right answer is almost always a structure that combines two or more of these jurisdictions, matched to the company';s stage, therapeutic focus, investor base, and commercialisation geography.

VLO Law Firms advises international clients on biotech company formation and structuring across multiple jurisdictions. We can assist with entity selection, IP holding structures, R&D incentive compliance, and cross-border corporate documentation. To request a consultation, contact: info@vlolawfirm.com